France

Poxel

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases

Lead Product(s): PXL770

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

PXL770 treatment was observed to improve cardio-renal disease and adrenoleukodystrophy (ALD) /adrenomyeloneuropathy (AMN) in animal models.

Poxel

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Poxel Successfully Raises €17.7 Million in a Capital Increase

Lead Product(s): PXL770

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: JMP Securities LLC

Deal Size: $19.4 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 25, 2020

Details:

The use of proceeds will enable the Company to accelerate the development plans for PXL770 and PXL065 for the treatment of NASH, to pursue development activities in other metabolic diseases and for general corporate purposes.

Inventiva S A

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Inventiva announces completion of patient visits for Phase IIb clinical study

Lead Product(s): Lanifibranor

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2020

Details:

Last patient last visit took place in the United States on March 16, 2020. Publication of study head-line results expected for June 2020.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Poxel

Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases

Poxel

Poxel Successfully Raises €17.7 Million in a Capital Increase

Inventiva S A

Inventiva announces completion of patient visits for Phase IIb clinical study